Email not displaying correctly? See online newsletter
HIV in Europe Newsletter
Issue No. 9 - October 2011

HIV in Europe Copenhagen 2012 Conference
19-20 March 2012, Copenhagen, Denmark

Call for Abstracts
The HIV in Europe Initiative invites interested delegates to submit an abstract to the HIV in Europe 2012 Conference, within the following categories:
  1. Lessons learned in the implementation of novel (national) HIV testing strategies and guidelines
  2. Approaches and results from the evaluation of testing programmes
  3. Scaling up HIV testing and earlier care among hard-to-reach and heavily affected populations
  4. HIV testing and the continuum of HIV care
  5. Characteristics of PLHIV who present late for HIV care
  6. Cost-effectiveness of HIV testing
  7. Implications of stigmatisation, criminalisation of HIV and other legal issues for the offer and uptake of HIV testing and earlier care
  8. Use and performance of new HIV testing diagnostic technologies
The deadline for submission of abstracts is 9 December 2011.

Abstract submission

Scholarship Applications
Scholarship applications are welcome from persons working with late presentation for HIV care, optimal testing and earlier care. Priority is given to applicants from Central and Eastern European and Central Asian countries and to applicants under 35 years. 

      Scholarship Application

European AIDS Clinical Society (EACS) Conference, 12-15 October 2011, Belgrade, Serbia
HIV in Europe is presenting results from HIDES 1 (HIV Indicator Diseases across Europe Study - results from the pilot phase)

and Professor Brian Gazzard will give a mini-lecture on the next steps of the HIV in Europe Initiative :

HIV in Portugal 2011
The HIV in Portugal national conference was held in Lisbon 30 September - 1 October.

For more information and other news related to the HIV in Europe 2012 Conference, please check the HIV in Europe website or contact the HIV in Europe Secretariat
+45 35455782

Financial support of the initiative has been provided by Gilead Sciences, Merck, Tibotec, Pfizer, Schering-Plough, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare and the Swedish Research Council.